Advanced Prostate Cancer: EMA Approves Abiraterone Combined With Hormone Therapy as First-line Treatment
News Nov 22, 2017 | Original story from The Institute of Cancer Research
Credit: The Institute of Cancer Research
The prostate cancer drug abiraterone has been approved by the European Medicines Agency in combination with standard hormone therapy for use as a first-line treatment for advanced prostate cancer.
Men with newly diagnosed prostate tumours that are ‘high risk’ or have already spread will be eligible for the combination, which was shown to delay progression of the disease by over a year longer than standard hormone treatment alone.
Abiraterone was discovered at The Institute of Cancer Research, London, and had already previously been approved for the treatment of advanced prostate cancer before chemotherapy in men for whom hormone therapy had failed.
The new decision was based on data from the international multicentre Phase III LATITUDE trial, which showed that the combination had a clear benefit when used earlier.
NICE is currently carrying out an appraisal for using abiraterone in this setting, and its decision is expected in 2018.
Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said:
“It is fantastic news that abiraterone has been approved by the European regulator as a first-line treatment in combination with hormone therapy for men newly diagnosed advanced prostate cancer.
“Drug therapy for prostate cancer has undergone a revolution over the last decade, and this is another big step forward – the first time that a modern, targeted therapy has been approved for use from the point of diagnosis.
“Abiraterone was discovered at the ICR, and has already improved the outlook for hundreds of thousands of men with the disease worldwide. Following fantastic results from clinical trial results published earlier in the year, it is clear that using abiraterone right at the start of treatment can be hugely beneficial – delaying cancer progression by over a year compared with standard hormone therapy alone.
“We hope that NICE and the manufacturer will work together to ensure that abiraterone is made available at an affordable price, so that the combination with hormone therapy can be approved for use on the NHS as soon as possible.”
This article has been republished from materials provided by The Institute of Cancer Research. Note: material may have been edited for length and content. For further information, please contact the cited source.
Targeted Drug Could be Used to Treat Advanced Cancers Located Anywhere in the BodyNews
A new targeted drug could be used to treat a small number of advanced cancers no matter where they grow in the body.READ MORE
Human Malaria Parasites Grown for the First Time in Dormant FormNews
One of the biggest obstacles to eradicating malaria is a dormant form of the parasite which is resistant to most antimalarial drugs and can reawaken years later, causing disease relapse. Researchers have shown they can grow the dormant parasite in engineered human liver tissue for several weeks, allowing them to closely study how the parasite becomes dormant, what vulnerabilities it may have, and how it springs back to life.READ MORE
Bacteria Produce More Substances Than Genetics PredictedNews
Tandem mass spectrometry has revealed that Streptomyces chartreusis, an antibiotic-producing bacterium, releases more metabolites into the surrounding medium than scientists assumed based on the analysis of the genome. They might include molecules that are of interest as potential pharmaceutical agents.READ MORE
Comments | 1 ADD COMMENT
Leonard Adams | Dec 08, 2017
I had no idea about this. My urologist is very opposed to drugs that have not undergone through rigorous clinical trials, I have BPH and he prescribed me alpharise health. It has been a very effective cure for my bph symptoms.